Who's going to carry the logs
Swing Trader
Merck looks cheap at 16x earnings when drugmakers usually get 20x. Fair value is roughly $168-214, or 20x next year's expected $9.57 EPS give or take 12%, putting the stock about 10% below the bottom of that range; it would be expensive above $215. The view leans on forecasts, with forward EPS 32% above trailing, and involves no fundamental work. x.comÂ
AbbVie looks cheap at 16 times earnings, against the 20 times drugmakers usually get. Fair value is $285.91 to $363.89, based on 20 times next year's $16.25 a share give or take 12%, so the $261.83 price sits 8% below the low end; it turns expensive above $307.61. The range leans on forecasts, with forward earnings 60% above trailing. This is a levels-only read off reported earnings and estimates, with no fundamental work. x.comÂ
Amgen shows signs of continued institutional buying and potential short-term strength. A $2.3 billion print and a $26 million roll into deep in-the-money calls both point that way, and its weekly entry candle resembles Union Pacific's. x.com x.comÂ
Pfizer is a true safe haven that looks cheap at $28 a share, trading below 10 times adjusted earnings. Its 6.1% dividend has been paid for more than 349 quarters in a row, a remarkable record, and sentiment across biotech is strong after news from Moderna and Merck. x.comÂ
Amgen is a large-cap healthcare pick for its pipeline, which holds interesting developments, and an upgrade cycle that is starting. x.comÂ